Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.

ington, D.C.: Government Printing Office, 1977. DHEW Publication No. (OS) 77-0004. 12. Ellis GB. Federal policy for protection of human subjects. In: Report on the Public Forum on Informed Consent in Clinical Research Conducted in Emergency Circumstances. Washington, D.C.: U.S. Food and Drug Administration /National Institutes of Health, 1995. 13. National Institutes of Health. NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects, March 1998 (http://www.nih.gov/ grants/guide/notice-files/not98024.html) 14. Food and Drug Administration Rules and Regulations 21 CFR 201, 312, 314, 601 (Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients; Final Rule). Federal Register 1998;63(231):66632. 15. Shirkey HC. Therapeutic orphans. Journal of Pediatrics 1968;72:119120. 16. American Academy of Pediatrics. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1977; 60:91-101.

[1]  J. Mathews,et al.  The communication process in clinical settings. , 1983, Social science & medicine.

[2]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[3]  Jeanne Holmes,et al.  Facing the 21st Century. , 1997 .

[4]  Searight Hr,et al.  Remembering and Interpreting Informed Consent: A Qualitative Study of Drug Trial Participants , 1996, The Journal of the American Board of Family Medicine.

[5]  P. A. Kelly,et al.  Readability of pediatric biomedical research informed consent forms. , 1990, Pediatrics.

[6]  H. Masur,et al.  The impact of disease severity on the informed consent process in clinical research. , 1996, The American journal of medicine.

[7]  M J Ratain,et al.  Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. , 1993, Journal of the National Cancer Institute.

[8]  H. Llewellyn-Thomas,et al.  Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. , 1991, Social science & medicine.

[9]  M. Markman.  Opinion: The ethical dilemma of phase i clinical trials , 1986, CA: a cancer journal for clinicians.

[10]  Jubelirer Sj.  Level of reading difficulty in educational pamphlets and informed consent documents for cancer patients. , 1991 .

[11]  B. Chabner,et al.  Pharmacologically guided phase I clinical trials based upon preclinical drug development. , 1990, Journal of the National Cancer Institute.

[12]  M. Ratain,et al.  Perceptions of cancer patients and their physicians involved in phase I trials. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Street,et al.  Information-giving in medical consultations: the influence of patients' communicative styles and personal characteristics. , 1991, Social science & medicine.

[14]  R. Levine,et al.  Clinical trials and physicians as double agents. , 1992, The Yale journal of biology and medicine.

[15]  K. Itoh,et al.  Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. , 1997, British Journal of Cancer.

[16]  C. Spurr,et al.  Informed consent: Patient information forms in chemotherapy trials , 1984, American journal of clinical oncology.

[17]  G. Kent,et al.  Shared understandings for informed consent: the relevance of psychological research on the provision of information. , 1996, Social science & medicine.

[18]  S. Rodenhuis,et al.  Patient motivation and informed consent in a phase I study of an anticancer agent. , 1984, European journal of cancer & clinical oncology.

[19]  F. Cavalli,et al.  Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  F. V. van Wijmen,et al.  Informed consent in clinical trials. , 1996, Health policy.

[21]  L. Yoder,et al.  Expectations and experiences of patients with cancer participating in phase I clinical trials. , 1997, Oncology nursing forum.

[22]  R. Holcombe,et al.  Informed consent for clinical trials: a comparative study of standard versus simplified forms. , 1998, Journal of the National Cancer Institute.

[23]  I. Olver,et al.  The adequacy of consent forms for informing patients entering oncological clinical trials. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  G. Decoster,et al.  Responses and toxic deaths in phase I clinical trials. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  H. Sass.  Ethical considerations in phase I clinical trials. , 1990, Onkologie.

[26]  M. Ratain,et al.  Study of cohort-specific consent and patient control in phase I cancer trials. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Judith A. Hall,et al.  Meta-analysis of Correlates of Provider Behavior in Medical Encounters , 1988, Medical care.

[28]  R. Lilford,et al.  Informed consent for clinical trials: in search of the "best" method. , 1998, Social science & medicine.

[29]  N. Lynöe,et al.  Informed consent: study of quality of information given to participants in a clinical trial. , 1991, BMJ.

[30]  T. Beauchamp,et al.  A History and Theory of Informed Consent , 1986, American Political Science Review.

[31]  E. Pellegrino,et al.  Beneficence, Scientific Autonomy, and Self-Interest: Ethical Dilemmas in Clinical Research , 1992, Cambridge Quarterly of Healthcare Ethics.

[32]  Paul S. Appelbaum,et al.  Informed Consent: Legal Theory and Clinical Practice , 1987 .

[33]  S. Piantadosi,et al.  Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families? , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  N. King.  Experimental treatment. Oxymoron or aspiration? , 1995, The Hastings Center report.

[35]  R. Schilsky,et al.  Prognostic factors for survival in patients treated in phase I clinical trials , 1994, Cancer.

[36]  D. Tritchler,et al.  Communicating probabilistic information to cancer patients: is there 'noise' on the line? , 1991, Social science & medicine.

[37]  M. Hawkins.  Early cancer clinical trials: safety, numbers, and consent. , 1993, Journal of the National Cancer Institute.

[38]  G. Morrow,et al.  How readable are subject consent forms? , 1980, JAMA.

[39]  H. Waitzkin.  Information giving in medical care. , 1985, Journal of health and social behavior.